Driven by industry, advocacy, policy, and investor insights, the Rare Disease Innovation & Partnering Summit brings together diverse stakeholders to discuss opportunities for continued innovation, advancement of impactful patient advocacy, and acceleration of commercial strategy success. Join experts across the rare disease community to unite in areas of unmet medical need and create life-transforming therapies and breakthroughs.
Join CENTOGENE for the Panel Discussion
The Future of Rare Disease Drug Development – Reflection Points Looking Forward
This panel will explore recent updates to the 21st Century Cures Act and impacts to the rare disease community. They will also be discussing the importance of continued innovation in a high-risk and rapidly evolving policy environment. Lastly, the panel will feature key takeaways from trends and discussions throughout the entire event’s program.
4 December 2020, 12:20 – 12:50 p.m. (Boston) / 5:20 – 5:50 p.m. (CET)
• Peter Bauer - Chief Genomic Officer, CENTOGENE
• Jen Beachell - Vice President, Commercial, Momenta Pharma
• Jocelyn Duff - Founder & CEO, Cure CMT4J
• John Maslowski - Chief Executive Officer, Castle Creek Biosciences
Please note that attending the Rare Disease Innovation & Partnering Summit Virtual Conference requires registration. For further information, please visit: <link https: informaconnect.com rare-disease-summit external-link-new-window external link in new>informaconnect.com/rare-disease-summit/